Critical Survey: CVRx (NASDAQ:CVRX) vs. Xcorporeal (OTCMKTS:XCRP)

Xcorporeal (OTCMKTS:XCRP) and CVRx (NASDAQ:CVRX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation.

Institutional & Insider Ownership

75.3% of CVRx shares are owned by institutional investors. 18.9% of CVRx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Xcorporeal and CVRx, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xcorporeal	0	0	0	0	0.00
CVRx	1	0	1	1	2.67

CVRx has a consensus target price of $11.50, indicating a potential upside of 118.26%. Given CVRx’s stronger consensus rating and higher possible upside, analysts clearly believe CVRx is more favorable than Xcorporeal.

Profitability

This table compares Xcorporeal and CVRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Xcorporeal	N/A	N/A	N/A
CVRx	-89.14%	-120.76%	-48.38%

Valuation & Earnings

This table compares Xcorporeal and CVRx”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xcorporeal	N/A	N/A	N/A	N/A	N/A
CVRx	$56.65 million	2.47	-$53.31 million	($2.02)	-2.61

Xcorporeal has higher earnings, but lower revenue than CVRx.

Summary

CVRx beats Xcorporeal on 7 of the 10 factors compared between the two stocks.

About Xcorporeal

Xcorporeal, Inc. is in the process of liquidation and dissolution, pursuant to the plan adopted by board of directors of the company on February 4, 2010. The company has formed the liquidating trust, Xcorporeal, Inc. Liquidating Trust, and transferred all of its assets to the trust for the purpose of completing the liquidation and dissolution of the company. Previously, it operated as a medical device company, which was engaged in the development of an extra-corporeal platform technology to be used in devices to replace the function of various human organs. Xcorporeal, Inc. was founded in 2001 and is based in Lake Forest, California.

About CVRx

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.